Eikon Therapeutics (NASDAQ:EIKN) Major Shareholder Acquires $1,031,152.00 in Stock

Eikon Therapeutics, Inc. (NASDAQ:EIKN) major shareholder Group Iv Gp Lp Column purchased 89,200 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were purchased at an average cost of $11.56 per share, for a total transaction of $1,031,152.00. Following the completion of the purchase, the insider owned 89,200 shares in the company, valued at $1,031,152. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Eikon Therapeutics Stock Performance

Shares of Eikon Therapeutics stock opened at $9.21 on Friday. The stock has a market capitalization of $498.91 million and a PE ratio of -2.25. Eikon Therapeutics, Inc. has a 52 week low of $7.90 and a 52 week high of $17.40. The stock has a 50 day moving average price of $10.46 and a two-hundred day moving average price of $10.81.

Eikon Therapeutics (NASDAQ:EIKN) last issued its earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). Research analysts forecast that Eikon Therapeutics, Inc. will post -7.24 EPS for the current year.

Institutional Investors Weigh In On Eikon Therapeutics

Several institutional investors have recently bought and sold shares of EIKN. Legal & General Group Plc purchased a new stake in Eikon Therapeutics in the 2nd quarter valued at $28,000. California State Teachers Retirement System bought a new stake in shares of Eikon Therapeutics in the 2nd quarter worth $51,000. Integrated Wealth Concepts LLC bought a new stake in shares of Eikon Therapeutics in the 2nd quarter worth $142,000. Citadel Advisors LLC purchased a new stake in shares of Eikon Therapeutics in the second quarter valued at about $170,000. Finally, Deutsche Bank AG purchased a new stake in shares of Eikon Therapeutics in the second quarter valued at about $281,000.

Analyst Ratings Changes

Several research firms have weighed in on EIKN. Wedbush lowered their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a report on Friday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a report on Friday, August 21st. Mizuho raised shares of Eikon Therapeutics to a “strong-buy” rating in a research report on Monday. Finally, Weiss Ratings upgraded shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Eikon Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.